This week, we will discuss the POTCAST trial. It is a cardiology trial - but potassium belongs to nephrology.
POTCAST: El Resumen Visual
¿Elevar el K⁺ al rango alto-normal puede reducir las descargas del DAI y las hospitalizaciones? POTCAST desafía nuestro miedo al potasio.
Revisa el resumen visual por Jeyakumar Meyyappan y únete a la conversación en #NephJC
POTCAST: The Visual Abstract
Can pushing K⁺ to the high-normal range reduce ICD shocks and hospitalizations? POTCAST challenges our fear of potassium.
Check out the VA by Jeyakumar Meyyappan and join the #NephJC conversation
TenPosts: pegcetacoplan in C3GN
Check out VALIANT recap: a 26-week analysis of the phase 3 trial of pegcetacoplan in C3GN! Thread by NephJC intern Bogdan Agavriloaei.
A VALIANT effort to combat complement disorders with pegcetacoplan
TenPosts PISCES
Check out PISCES recap: a whale of a tale of fish oil and cardio-protection in ESRD! Thread by NephJC intern Sai Vani
ORIGIN 3 interim-story: atacicept in IgAN
Check out ORIGIN 3 recap: a 36-week, interim analysis of phase 3 trial of atacicept in IgAN! Thread by NephJC intern Marc Soco.
A dose of CONFIDENCE: Building evidence for finerenone-empagliflozin synergy in diabetic kidney disease
Advance-HTN: Return of the systolic order – Lorundrostat’s role in restoring balance
Does Lorundrostat Effectively Lower Blood Pressure in Uncontrolled Hypertension?
Stunning visual abstract summarizing NEJM study, by Priti Meena
Is a lower BP the road to better outcomes in diabetes?
How low is too low for blood pressure? Will BPROAD get to the bottom of this issue?
Microvascular inflammation of kidney allografts
Microvascular inflammation from the perspective of a real unicorn: donor-specific antibodies with negative antibody mediated rejection 🦄
